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Abstract
Doxorubicin is an anthracycline antibiotic that is among one of the most commonly used chemotherapeutic agents in the
clinical setting. The usage of doxorubicin is faced with many problems including severe side effects and chemoresistance.
To overcome these challenges, it is important to gain an understanding of the underlying molecular mechanisms with
regards to the mode of action of doxorubicin. To facilitate this aim, we identified the genes that are required for doxorubicin
resistance in the fission yeast Schizosaccharomyces pombe. We further demonstrated interplay between factors controlling
various aspects of chromosome metabolism, mitochondrial respiration and membrane transport. In the nucleus we
observed that the subunits of the Ino80, RSC, and SAGA complexes function in the similar epistatic group that shares
significant overlap with the homologous recombination genes. However, these factors generally act in synergistic manner
with the chromosome segregation regulator DASH complex proteins, possibly forming two major arms for regulating
doxorubicin resistance in the nucleus. Simultaneous disruption of genes function in membrane efflux transport or the
mitochondrial respiratory chain integrity in the mutants defective in either Ino80 or HR function resulted in cumulative
upregulation of drug-specific growth defects, suggesting a rewiring of pathways that synergize only when the cells is
exposed to the cytotoxic stress. Taken together, our work not only identified factors that are required for survival of the cells
in the presence of doxorubicin but has further demonstrated that an extensive molecular crosstalk exists between these
factors to robustly confer doxorubicin resistance.
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Introduction
Doxorubicin (DOXO)(trade name adriamycin) is an anthracy-
cline antibiotic that ranks among the most useful anti-neoplastic
agents used against a wide range of cancers including that of
breast, prostrate, oesophageal, stomach, liver; sarcomas and
hematological malignancies [1,2]. DOXO acts by inhibiting the
DNA topology regulating enzyme topoisomerase II (Top2), which
relieves torsional stress on the chromatin generated during DNA
transactions such as transcription and DNA replication via
transient formation of DNA double stranded breaks (DSB) [3,4].
Poisoning of Top2 presumably results in accumulation of DSB
that eventually leads to cell death [3,5]. In combination with
formaldehyde, DOXO can also form DNA interstrand crosslink-
like adducts, which interfere with DNA replication [5]. Notwith-
standing the effect on DNA, DOXO has been reported to disrupt
mitochondrial membrane lipid cardiolipin and induce oxidative
stress and production of reactive oxygen species [1,2].
A major challenge in the usage of DOXO lies in the control of
the administration dose as increase dosage heightens the pro-
pensity of adverse drug-linked cytotoxic effect, especially cardio-
toxicity [1,2]. Another problem in DOXO usage is the rapid
development of resistance by the cancer cells [6]. The underlying
molecular mechanisms causing drug resistance is still largely
unresolved, which make the management of it difficult. Hence an
understanding of the basic mechanisms employed by cells to resist
the ill effects of DOXO is essential to fine-tune drug usage to
achieve maximum killing of malignant cells yet minimizing
cytotoxic side effects.
One way to address this issue is via identification and
elucidation of the molecular players and pathways modulating
DOXO resistance. We therefore embarked on an unbiased genetic
screen using the model organism fission yeast Schizosaccharomyces
pombe aiming to uncover fundamental mechanisms regulating
DOXO resistance (DXR). We identified independent mutations in
91 DXR genes that were required for resistance against DOXO
from a collection of 3225 single gene deletion mutants. These
DXR factors function in multiple distinct complexes that acted in
several sub-cellular locations. We have further shown that these
DXR factors also cooperated to form an extensive network to
maintain cell viability in the presence of DOXO. Hence the work
reported here suggests that resistance to DOXO was controlled by
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a web of interlinking pathways and the knowledge derived are
expected to be useful for facilitating selection of diagnostic targets
for combination chemotherapy in conjunction with DOXO in
human cells.
Experimental Procedures
Strains, media and drugs. Fission yeast haploid gene
deletion library (Bioneer ver2.0) [7] was used for genome-wide
screens with the supplied wild-type and Drav1 [8] strains as
negative and positive controls respectively. Strains were tested by
growing to exponential phase followed by spotting individual ten-
fold serially diluted strains manually on agar media containing
DOXO and incubated at 26uC for three to four days. Prototrophic
strains were derived from backcrossing auxotrophic Bioneer
library strains with prototrophic 972 (h2) strain using classical
genetic techniques. YEA (3% glucose, 0.5% yeast extract, 75 mg/
L adenine) media was used to grow fission yeast cells. The gene
disruption for each strain according to Bioneer was confirmed by
checking for the replacement of endogenous open reading frame
of each gene with the kanamycin disruption cassette using PCR.
Determination of DOXO hypersensitivity of mutant
strains. DOXO hypersensitivity of the single mutants (SM)
was determined by spotting prototrophic mutant strains at 75 mg/
ml DOXO. Strains that did not show hypersensitivity were
retested on 165 mg/ml, and further at 310 mg/ml. Strains which
showed hypersensitivity at 75, 165, and 310 mg/ml DOXO were
denoted as strong, medium and weak mutants respectively.
Analysis of genetic interactions were performed by comparing
the fold sensitivity (relative to wild-type (WT) cells) of the double
mutant (DM) to that of the single mutants and then normalizing to
the growth of the DM on media without drug. A DM strain was
deemed to show synthetic growth defect if its relative fold
hypersensitivity on DOXO was higher than both the parental
SMs, whereas in the case of non-synthetic growth defect, the
relative fold hypersensitivity of the DM was similar to the parental
strain that exhibited higher fold hypersensitivity.
Results
Identification of Doxorubicin Resistance (DXR) Genes in
Fission Yeast
To find genes essential for chemoresistance against doxorubicin
(DOXO), we began by examining the cytotoxicity of DOXO on
fission yeast cell. This was achieved by determining the viability at
a range of different DOXO concentrations (Fig. 1). Viability of
wild-type cells remained high over the range tested until 300 mg/
ml (Fig. 1) while a mutant of the gene encoding a regulator of
assembly of V-ATPase (Drav1) showed hypersensitivity to DOXO
as reported before [8]. We chose 75 mg/ml (129 mM) that
represented a .LC50 dose that killed .50% of Drav1 cells
(Fig. 1) to search in an unbiased manner for strains that exhibited
hypersensitivity to DOXO from among 3225 fission yeast single
gene deletion strains. This collection consisted of 2997 strains from
Bioneer ver2.0 library and 228 strains from ver1.0 but absent in
ver2.0 library [7] (Fig. 2). The ver1.0 strains have been back-
crossed with wild-type strain to obtained prototrophic mutants.
The strains were tested by manually spotting ten-fold serially
diluted exponentially growing cells on solid media containing
75 mg/ml DOXO. Repeatability of the DOXO-hypersensitive
phenotype of the strains was confirmed by spotting the strains at
least four times on DOXO-containing agar media. Furthermore,
we also performed backcross to introduce the gene deletion
mutations into a prototrophic background so as to ascertain that
the DOXO hypersensitivity was specific to the null mutation and
unaffected by the genetic background of the strains (Fig. 2). Of the
116 DXR strains obtained from the primary and secondary
screens, 91 strains remained hypersensitive to DOXO in pro-
Figure 1. Cytotoxicity of wild-type and Drav1 cells to concentrations of DOXO ranging from 0 to 300 mg/ml. Exponentially-growing cells
were treated with the indicated level of DOXO for 4 hours. Cell viability was estimated by the number of colonies that was formed after seven day
incubation from 200 cells plated on rich media without drug, and expressed as a proportion to the untreated sample. Wild-type cells did not show
decrease in viability over the range tested, while Drav1 showed .50% loss in viability at 75 mg/ml.
doi:10.1371/journal.pone.0055041.g001
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totrophic background (Fig. 2). The remaining 27 null mutations
failed to show DOXO hypersensitivity in the prototrophic genetic
background indicating that the phenotype may arise from genetic
interaction between the nutrition marker gene mutations and the
respective gene deletions (Fig. 2). These strains were hence
excluded from further analysis. The viability loss demonstrated by
these 91 hypersensitive strains showed that the deleted genes from
each of the strains were required for conferring DOXO resistance
(DXR) to the cells. These mutants were shown to be sensitive at
varying concentrations of DOXO (Fig. 2, Table S1) with 45
strongly, 42 medium and 4 weakly sensitive strains, showing
hypersensitivity at 75 mg/ml, 165 mg/ml and 310 mg/ml DOXO
respectively (Fig. 3A, B, C, S1, Table S1). Several strains exhibited
considerable growth defect already in the absence of the drugs
(Fig. S1). However these were still categorized as DXR strains due
to the additive growth defect on exposure to the drug (Fig. S1). We
noticed that most of the DXR genes possess counterparts in
budding yeast and a significant number (52 out of 91, 57.1%)
showed high similarity to human proteins (Table S1) as identified
using Homologene (NCBI) and Pombase (Sanger Center)
databases.
Functional Analysis of DXR Genes
Next we used Gene Ontology Local Exploration Map
(GOLEM) (http://go.princeton.edu/cgi-bin/GOTermFinder) to
classify the DXR genes into different functional categories. At
a statistical confidence of p,0.01, GOLEM allocated 44 genes to
nuclear processes related to chromatin remodeling, histone
modification (acetylation in particular), chromosome structure
maintenance and segregation, homologous recombination (HR)
and DNA repair pathways (Fig. S2). Six genes were classified in
mitochondrial respiration pathways by GOLEM (Fig. S3), which
also identified many genes encoding membrane associated trans-
porter proteins (Table S1). Coupling with published data and
information from PomBase (Sanger Center), we were able to
divide the DXR mutants into 11 physiological pathways (Table
S1, Fig. 4A). Approximately 80% of the DXR factors localized to
three subcellular compartments, namely nucleus (43 of 91, 47.3%),
mitochondria (17 of 91, 18.7%) and endosomal membranes (11 of
91, 12.1%) (Fig. 4B).
Several distinct complexes were identified among the nuclear
DXR factors that include Ino80 (Nht1, Iec1, SPCC16C4.20c,
Ies6, Iec3, Ies4, Arp5, Arp8) [9], RSC chromatin remodelers
(Arp42, Rsc1, Rsc4) [10], SAGA histone acetyltransferase complex
Figure 2. Workflow of the screening procedure to uncover genes required for DOXO resistance (DXR). A total of 3225 strains made up
of 2997 strains from Bioneer ver2.0 library and 228 unique backcrossed strains from ver1.0 were screened. Each of the auxotrophic ver2.0 strains was
serially diluted and manually spotted on 75 mg/ml DOXO and 116 strains were found to be repeatedly showing hypersensitivity on DOXO. These
strains were backcrossed with prototrophic wild-type cells to remove all the nutrition marker mutations in the Bioneer strains in order to link the
DOXO hypersensitive phenotypes to the indicated null mutations. 91 strains that showed hypersensitivity to various level of DOXO were obtained
finally.
doi:10.1371/journal.pone.0055041.g002
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(Gcn5, Ngg1, Ada2) [11], and DASH complex that controls
microtubule-kinetochore attachment (Duo1, Spc19, Dad2, Dad3,
Dad5) [12]. We also found many mutants of enzymes catalyzing
biosynthesis of coenzyme Q, a major anti-oxidant that functions in
mitochondria as electron transducer (coq2, coq3, coq4, coq6, coq7,
and dps1) [13] (Fig. S3), as well as mutants of several subunits of
the mitochondrial respiratory chain complexes (Pombase)(Fig. 4B,
Table S1).
Crosstalk between DXR Genes Confers Cellular
Robustness in Doxorubicin
We performed epistasis analyses to assess the actual functional
link between the DXR factors. To this end, we combined the null
mutations together using genetic crosses and examined the
hypersensitivity of the resultant double mutants (DM) relative to
the corresponding single mutants (SMs). Cumulative hypersensi-
tivity shown by the DM over the SM indicates that the factors
function in separate biological pathways. In contrast, for factors
interacting with each other in the similar pathways, the DM would
be expected to exhibit no cumulative DOXO hypersensitivity
[14]. We concentrated our studies on the factors classified under
the three major ontological components, namely nuclear chroma-
tin, mitochondrial and endosomal regulation.
Epistasis analyses were carried out between mutants of the
subunits within the Ino80 and DASH complexes (Ino80: Dnht1,
Dspcc16c4.20c and Diec1, and DASH: Ddad2, Ddad3 and Ddad5)
(Table S1). The lack of synthetic hypersensitivity exhibited by the
DMs on DOXO compared to the SMs suggests that the whole
complexes may be important for DOXO response and the
Figure 3. Prototrophic DXR haploid deletion strains showed differential sensitivity to DOXO. Hypersensitivity demonstrated by DXR
strains at (A) 75 mg/ml, (B) 165 mg/ml and (C) 310 mg/ml DOXO. Exponentially growing prototrophic strains were ten-fold serially diluted and
individually spotted on DOXO-containing plates.
doi:10.1371/journal.pone.0055041.g003
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subunits likely did not reorganize into different synergistically-
acting sub-complexes (Fig. S4, S5). We showed that the two HR
factors Rhp54 and Rhp55 also function in the same complemen-
tation group similar to the response exhibited towards several
other DNA damaging agents [15]. The positive interaction
exhibited by these two HR mutants on DOXO was suggestive
Figure 4. Functional classification and sub-cellular localization of DXR factors. (A) DXR factors were classified into 11 ontological groups.
Vertical axis indicates the number of genes in each class. (B) Model of molecular mechanism for DOXO resistance in fission yeast. Cooperation of
chromosome associated complexes that remodel and coordinate proper response to DNA damage were probably required for precise management
of DOXO-induced DNA lesions. In addition, mitochondrial function and membrane transporters localized to various cell compartments that control
intracellular accumulation of DOXO also determined the sensitivity of cells to the drug. Several factors including the COP9-Signalosome may facilitate
repair of DOXO lesion via regulation of nucleotide synthesis.
doi:10.1371/journal.pone.0055041.g004
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of a closer relationship that may involve physical interaction [16].
Interestingly, we found that Ssb3, the single stranded DNA
binding factor that facilitates repair of DNA replication-associated
damage [17] also belonged to the same epistatic pathway as
Rhp55 (Fig. S6). However, Dssb3 showed synthetic growth defect
with Drhp54, suggesting that there exists subdivision of pathways
within the HR group proteins in respond to DOXO (Fig. S6).
Next we tested the genetic interaction between several nuclear-
localizing complexes, namely DASH, Ino80, SAGA, RSC and the
HR proteins [9,10,11,15,18]. We observed synthetic growth
defects between Ino80 and HR factor mutants with that of DASH
subunits (Drhp54Ddad5 and Drhp55Ddad5, weaker effect in
Drhp54Ddad2 and Drhp55Ddad3), suggesting that the chromatin-
localizing Ino80 and HR proteins may cooperate in parallel with
DASH complex, which regulates precise chromosome segregation
[12] to confer DOXO resistance in fission yeast cells (Fig. 5A and
5B). Consistent with this hypothesis, mutants of Ino80 and HR
factors showed no cumulative increase in DOXO hypersensitivity
with the mutants of other chromatin acting complex subunits
(SAGA, Fig. S7 and RSC, Fig. S8). Furthermore, no DOXO-
dependent synthetic growth defect was observed between mutants
of the Ino80 subunit iec1 and single stranded DNA binding Ssb3,
which is in the same epistasis group as Rhp55 (Fig. 5D, S6). Taken
together, these epistasis studies suggest that the HR, Ino80, SAGA
and RSC proteins may function closely to confer DOXO
resistance, possibly by coordinating the repair of DOXO-induced
DNA aberration. Interestingly, we observed that Ddad2 SM
showed non-synthetic interaction with Drhp55 SM (Fig. 5A),
suggesting that there may exist yet undefined functional overlap
between the DASH complex and Rhp55.
In addition, further analyses showed that the above-mentioned
nuclear factors functioned distinctly from the membrane trans-
porters (Pmd1 and V-ATPase regulator Rav1, the synthetic effect
with Drav1 was weaker) (Fig. 6A, 6B), and mitochondrial pathway
involving coenzyme Q biosynthesis (Coq2)(Fig. 6C, 6D) as the
DMs were more sensitive to DOXO than the corresponding SMs.
Taken together, our results suggest that there exist two major
mechanisms, one dependent on DASH complex and the other on
Ino80/HR/RSC/SAGA that worked in sync to counteract the
cytotoxic effect of DOXO. In the meantime, these nuclear factors
were integrated into a larger network that involved synergistically
acting mitochondrial ATP synthesis factors and membrane
transporter proteins, thus conferring DOXO resistance (Fig. 7).
Discussion
Here we report the identification of genes constituting an
extensive network regulating resistance against the chemothera-
peutic drug doxorubicin (DOXO). Such genetic crosstalk occurred
between many macromolecular complexes in several sub-cellular
locations, in particular nucleus, mitochondria and endosomal
membranes, which cooperate to ensure cell viability when
challenged with the cytotoxic drug. Our analyses hence empha-
sized the importance of interplay between molecular factors in the
control of chemotherapeutic drug response, which is likely to be
a universal mechanism controlling the resistance against chemo-
therapeutic drugs.
Redundancy between cellular pathways has been proposed to
confer robustness of cells to external perturbation [19,20].
Consistent with this model, we observed that prominent cell
death in DOXO seldom resulted from disruption of a single DXR
gene but simultaneous abrogation of two or more factors was
required. Interestingly, we noticed several DOXO-specific genetic
interactions between DXR genes that were not observed in the
absence of the drug. This suggests that cellular pathways can be
dynamically ‘‘rewired’’ when challenged with DOXO. Such
capability to remodel their genetic connectivity possibly underlies
the flexibility that enable cells to respond only when disturbances
are present, thus optimizing the utilization of cellular resources to
achieve maximum efficiency of the living system [21].
As compared to a similar screen that isolated DOXO-
hypersensitive strains from the budding yeast, there were several
overlapping groups of DXR genes with the screen reported here
[22]. Among these were genes encoding several HR protein
including SpRhp51/ScRAD51, SpRhp55/ScRAD55, SpRad32/
ScMre11 (S. pombe (Sp) and S. cerevisiae (Sc)) [23]. Mutants of these
genes were among the most sensitive to DOXO, strongly
suggesting that HR-regulated DNA repair pathway is a conserved
response to resolve DOXO-induced DNA adducts in both yeasts.
Besides HR, genes encoding protein subunits of the SAGA, RSC
Figure 5. Functional crosstalk shown by the genetic interaction
between nuclear DXR factors. (A) Genetic interaction between
mutants of DASH complex (Ddad2, Ddad3, and Ddad5) and HR genes
(Drhp54 and Drhp55). (B) Mutant of Ino80 subunit Diec1 showed
synthetic negative effect with that of DASH mutant Ddad3. (C) Ino80
mutant Diec1 showed no synthetic growth defect with the HR mutants
Drhp54 and Drhp55 suggesting that Ino80 function in the same
pathway with HR genes to modulate resistance to DOXO. (D) Lack of
synthetic growth defect between Ino80 mutant Diec1 and that of the
single-stranded DNA binding protein Ssb3.
doi:10.1371/journal.pone.0055041.g005
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and Ino80 complexes and that in endosomal sorting pathway were
also identified [10–12,22]. The major differences between the
genes obtained from the two screens were the membrane
transporter group that include fission yeast homologue of human
P-gp, the chromosome segregation regulator DASH complex and
the anti-oxidant coenzyme Q biosynthesis genes [6,12,13], which
were found as major hits in our list but were not isolated from
budding yeast. In terms of specific genes, there was surprisingly
low degree of overlap between the two yeasts (seven out of 71
genes obtained by Xia et al. [22]). However more similarity was
observed when the DOXO-responsive molecular pathways were
considered.
Multiple mutants of the Ino80 complex subunits exhibited
hypersensitivity to DOXO were obtained in our screen. Ino80 is
a member of the SWI/SNF family ATP-dependent chromatin-
remodeling complex that functions in DNA DSB repair and
transcription from yeast to human [9,23–25]. Interestingly, our
genetic analysis observed no (or very marginal) upregulation of
DOXO hypersensitivity in double mutants of Ino80 subunit
(Diec1), the HR genes (Drhp54, Drhp55) and Dssb3, showing that
Ino80 complex and the HR proteins probably function in the same
pathway. In addition, we also observed no synthetic defect
between the mutant of SAGA catalytic subunit (Dgcn5) and that
of HR or Ino80 complex, suggesting that all these machineries
closely cooperate to mediate repair of DOXO-induced lesions,
possibly in the recruitment of DNA damage response factors.
It is not absolutely clear regarding the nature of the lesions arise
from DOXO exposure but the drug has been associated with
formation of DNA double-stranded break (DSB) [3] and DNA
interstrand crosslink-like aberrations that can also result in DSB
Figure 6. Synergistic effect between the nuclear, mitochondrial and membrane transport pathways to counteract DOXO
cytotoxicity. Genetic interaction between the genes encoding membrane transporters (Drav1 and Dpmd1) and (A) HR (Drhp55), (B) Ino80 (Diec1),
and DASH subunits (Ddad3 or Ddad5). Genetic interaction between mitochondrial coenzyme Q biosynthesis enzyme (Dcoq2) and (C) HR (Drhp55), and
(D) DASH subunit (Ddad3). All of the mutant pairs showed prominent synthetic growth defect, except Drhp55Drav1 of which the synthetic growth
defect was weak and masked by the strong drug-independent growth defect of the DM.
doi:10.1371/journal.pone.0055041.g006
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when the replication fork clashes into such structure [5].
Homologous recombination (HR) pathway is essential for the
repair of DOXO-associated DNA lesions in both scenarios [5]. It
is therefore not surprising that our screen and that in budding
yeast [22] identified mutations in HR genes to result in DOXO
hypersensitivity. Interestingly, our results identified the Rpa3-like
single stranded DNA binding protein Ssb3 functioning in the same
epistasis group as the HR protein Rhp55. Ssb3 is required for
repair of DNA lesions during S phase of the cell cycle [17],
supporting the hypothesis that DOXO induced chromosomal
conformation change that impede the progress of the replication
fork. Furthermore, we also identified human MHF1- and MHF2-
like proteins, which interact and facilitate the Fanconi anemia
nuclear core complex in resolving branched DNA structure
including replication fork [26], further supporting the formation of
DNA adducts that resulted in replication fork stalling in DOXO.
Together with the epistatic relationship between the SWI/SNF
ATP-dependent chromatin remodeling Ino80, SAGA histone
acetyltransferase and RSC complexes with the HR proteins, we
propose a model in which nucleosome remodeling and establish-
ment of opened chromatin conformation via histone acetylation
facilitate repair of DOXO adducts by HR factors and Ino80
complex probably during S-phase.
Remarkably, we isolated several enzymes participating in the
biosynthesis of coenzyme Q/ubiquinone, which is a strong anti-
oxidant [13] essential for maintaining the cell viability in the
presence of DOXO in fission yeast. Coenzyme Q is the major
electron carrier in the mitochondrial electron transport chain
relaying electron between NADH dehydrogenase (complex I) and
succinate dehydrogenase (complex II) to CoQ:cytochrome c
reductase (complex III) [13]. In the human cells, proper
mitochondrial function is important for resistance against DOXO
and the increased inhibition of mitochondrial oxidative phosphor-
ylation that leads to attenuation of ATP production by DOXO has
been suggested to underlie DOXO dose-dependent cardiotoxicity
[27]. In accordance with the anti-oxidant effect, coenzyme Q is
sold as a dietary supplement in the market and the intake has been
deemed to be beneficial for human heart function and to reduce
the risk of cardiotoxicity during chemotherapeutic regiments
[28,29]. Our results throw a cautionary note to the consumption of
coenzyme Q supplement during chemotherapy, as the extrapola-
tion of that to the human cells suggest that coenzyme Q may also
aid in the development of drug resistance by the cancer cells.
The development of drug resistance is a big hurdle that
challenges the efficacy of chemotherapeutic treatment of cancers
[6]. One major mechanism that contributes to drug resistance of
the cancer cells is the upregulation of efflux transporter activity
that results in extrusion of drug by the cancer cells [6].
Permeability-glycoprotein (P-gp) is an ABC type drug efflux
transporter that commands great clinical interest and is the major
transporter involved in extrusion of doxorubicin from the cell
[30,31,32]. Overexpression of P-gp is closely associated with the
development of multidrug resistance in the cancer patients [33].
Much effort has been devoted to targeting of P-gp to reverse
multidrug resistance during chemotherapy but with marginal
success [6,31]. Our results here provide evidence that one main
reason for this setback may lie in the existence of a complex
interaction between redundant pathways that act together with the
membrane transporters P-gp. The presence of such crosstalk will
pose a difficulty for pharmaceutical intervention against specific
efflux transporters. However, the definition of such molecular
crosstalk may facilitate the identification of diagnostically impor-
tant target proteins for pharmacological intervention, which may
be useful for counteracting drug resistance in the human cells.
Conclusions
Here we report the identification of 91 genes that were required
for resistance against the anti-cancer drug doxorubicin in fission
yeast. These genes include chromatin remodelers and chromo-
some segregation complexes that genetically cooperate with one
another in the nucleus, which also synergize with components of
electron transport chain in the mitochondria and efflux transpor-
ters on endosomal membrane. Such extensive redundancy was
deemed to promote cellular robustness in the presence of the drug.
The observed network may be used as a basis to study and
improve the efficacy of doxorubicin usage via targeted intervention
to sensitize human cancer cells to the drug.
Supporting Information
Figure S1 DOXO-hypersensitive strains that showed
significant retarded growth in the absence of the drug.
Several strains identified from our screen to show hypersensitivity
to DOXO were classified as strong/medium sensitive strains
according to the drug levels at which they were sensitive at.
However, these mutants were already showing much reduced
growth retardation on medium without drug, with only two of the
most concentrated spots grown. These mutants include (A) Dctp1,
Dies6, and Drad32 that showed hypersensitivity at 75 mg/ml
DOXO and (B) Darp5, Dmcl1 and Dspbc17a3.05c that were
sensitive at 165 mg/ml DOXO.
(TIF)
Figure S2 Ontological classification of DXR genes
generated using GOLEM. All highly significant DXR genes
were allocated by GOLEM to pathways related to regulation of
DNA damage response, homologous recombination, chromosome
Figure 7. Diagrammatic representation that depicts synergistic
relationship between the nuclear, mitochondrial and endoso-
mal membrane transporter genes. Lines with double arrow heads
represent synthetic growth defect exhibited by the double mutants in
different subcellular locations indicative of a synergistic relationship
between components at these locations. Within the nucleus, chromatin
modulating factors that act in similar epistatic group are joined by bold
lines and these factors generally function in parallel to the DASH
complex (dotted line). ‘?’ indicates undefined link between DASH and
HR (Rhp55) factors. The composite crosstalk between the factors acting
within and between each cellular compartment contributes to the
resistance against DOXO in fission yeast.
doi:10.1371/journal.pone.0055041.g007
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structure maintenance and chromosome segregation, chromatin
remodeling and histone acetylation. The genes depicted in this
chart were enriched in several distinct macromolecular complexes,
namely the microtubule connector at kinetochore DASH (Duo1,
Spc19, Dad1, Dad2, Dad3, Dad5), chromatin remodeler Ino80
(Nht1, SPCC16C4.02, Iec1, Ies2, Iec3, Ies4, Ies6, Arp5, Arp8),
chromatin remodeler RSC (Rsc1, Rsc4, Arp42), SAGA (Gcn5,
Ngg1, Ada2) and several HR factors (Rhp51, Rhp54, Rhp55).
(TIF)
Figure S3 Coenzyme Q biosynthesis genes were essen-
tial for DOXO resistance in fission yeast. Coq2, Coq4,
Coq6, Coq7 and Dps1 were identified by GOLEM to function in
the ubiquinone/coenzyme Q biosynthetic pathway.
(PDF)
Figure S4 Genetic interaction between components of
the Ino80 complex. Mutants of the Ino80 complex subunits
showed no cumulative sensitivity to DOXO in double mutant
combination over single mutants suggesting that they function in
the same complex to regulate DOXO resistance. (A) Single and
double mutants between Iec1, Spcc16c4. 20c and Nht1 were ten-
fold serially diluted and spotted on plates incorporated with the
indicated concentrations of DOXO. (B) Schematic representation
of the close relationship between Iec1, Spcc16c4. 20c and Nht1.
Double arrowhead lines depict no synthetic effect.
(TIF)
Figure S5 Genetic interaction between subunits of the
DASH complex. Lack of cumulative DOXO hypersensitivity
between mutants of different subunits of the DASH complex. (A)
Single and double mutants between Dad2, Dad3 and Dad5 were
ten-fold serially diluted and spotted on plates incorporated with
the indicated concentrations of DOXO. (B) Schematic represen-
tation of the close relationship between Dad2, Dad3 and Dad5.
Double arrowhead lines depict no synthetic effect.
(TIF)
Figure S6 Genetic interaction between homologous re-
combination DXR genes. Genetic interaction between the
single stranded DNA binding protein Ssb3 with the HR proteins
Rhp54 and Rhp55 in DOXO. (A) Rhp54 and Rhp55 showed
positive genetic interaction. Ssb3 was epistatic with Rhp55
suggesting that Ssb3 function in the same pathway with Rhp55.
On the other hand, Dssb3Drhp54 showed cumulative hypersensi-
tivity over the single mutants. (B) Schematic representation of the
close relationship between Ssb3, Rhp54 and Rhp55. Double
arrowhead lines depict no synthetic effect. Single arrowhead
represents synthetic suppression with the mutant pointed by the
arrow being suppressed. Double blunt ended line represents
synthetic growth defect.
(TIF)
Figure S7 Homologous recombination factors, SAGA
and Ino80 complex subunits formed a single epistatic
group. (A) Mutants of the SAGA complex (Dgcn5), Ino80 complex
(Diec1) and homologous recombination factor (Drhp55) were
serially diluted and then manually spotted onto agar media
containing the indicated concentrations of DOXO. Dgcn5Diec1
double mutant showed no cumulative hypersensitivity relative to
single mutants, indicating that these components of the three
complexes were in the similar epistasis group. (B) DOXO
hypersensitivity of Drhp55Dgcn5 was equivalent to Drhp55, which
is the weaker of the two single mutants at the level of DOXO
tested, showing that Rhp55 function in the similar epistatic group
with Gcn5. (C) Schematic representation showing lack of synthetic
growth defect (double arrowhead lines) between the mutants of
SAGA (Dgcn5), Ino80 (Diec1) and HR(Drhp55) subunits.
(TIF)
Figure S8 Homologous recombination, chromatin re-
modeler RSC complex and Ino80 complex subunits
formed a single epistatic group. (A) Mutants of the SAGA
complex (Drsc4), Ino80 complex (Diec1) and homologous re-
combination factor (Drhp55) were tested as in Fig. S8. Drsc4Drhp55
and Drsc4Diec1 double mutant showed no cumulative hypersen-
sitivity relative to single mutants. (B) Schematic representation of
the relationship between Rsc4, Iec1 and Rhp55. Double
arrowhead lines represent epistatic interaction accompanied by
no cumulative increase in DOXO hypersensitivity relative to the
single mutants.
(TIF)
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